Vaccine Efficacy Insights
Jay discusses the limitations of early vaccine trials, highlighting that they primarily focused on symptomatic Covid prevention rather than long-term outcomes like death rates. He emphasizes the need for better representation of older populations in studies, as they were the most affected by Covid. Additionally, he notes that while initial trials showed lower symptomatic Covid rates in vaccinated individuals, they did not adequately assess transmission or mortality outcomes.In this clip
From this podcast
Huberman Lab
Improving Science & Restoring Trust in Public Health | Dr. Jay Bhattacharya
Related Questions